XELOX方案在消化道肿瘤中的应用进展

Progress of the XELOX regimen applied in gastrointestinal cancer

在结直肠癌(colorectal cancer,CRC)的一线治疗、辅助治疗及新辅助治疗中,铂类药物奥沙利铂与氟尿嘧啶类药物卡培他滨联合应用的XELOX方案疗效优于或相当于FOLFOX方案。在晚期胃癌及其他消化道恶性肿瘤的治疗中,XELOX方案毒性及不良反应较轻,应用日益广泛。文中综述近年来XELOX方案在消化道肿瘤中的应用进展。

The combination of Oxaliplatin and Capecitabine（XELOX）has a synergic effect,which was demonstrated non-inferior to the FOLFOX regimens.The regimen has a activated effect that served as adjuvant therapy,neoadjuvant therapy and the first-line therapy in colorectal cancer,and had been applied in the advanced gastric cancer and other gastrointestinal cancers.The XELOX regimen was toxicity well tolerant and more convenient to administer than FOLFOX regimens,thus the application is continually increasing.This review presented the recent progression in the application of XELOX regimen in gastrointestinal cancers.